vs
IMMUCELL CORP（ICCC）与NEOGEN CORP（NEOG）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是IMMUCELL CORP的40.8倍（$224.7M vs $5.5M）。IMMUCELL CORP净利率更高（-2.5% vs -7.1%，领先4.5%）。NEOGEN CORP同比增速更快（-2.8% vs -8.4%）。NEOGEN CORP自由现金流更多（$7.8M vs $-1.8M）。过去两年IMMUCELL CORP的营收复合增速更高（3.9% vs -0.9%）
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
ICCC vs NEOG — 直观对比
营收规模更大
NEOG
是对方的40.8倍
$5.5M
营收增速更快
NEOG
高出5.6%
-8.4%
净利率更高
ICCC
高出4.5%
-7.1%
自由现金流更多
NEOG
多$9.6M
$-1.8M
两年增速更快
ICCC
近两年复合增速
-0.9%
损益表 — Q3 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $5.5M | $224.7M |
| 净利润 | $-139.7K | $-15.9M |
| 毛利率 | 42.9% | 47.5% |
| 营业利润率 | 0.4% | -2.4% |
| 净利率 | -2.5% | -7.1% |
| 营收同比 | -8.4% | -2.8% |
| 净利润同比 | 80.1% | 96.5% |
| 每股收益（稀释后） | $-0.02 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICCCNEOG
| Q4 25 | — | $224.7M | ||
| Q3 25 | $5.5M | $209.2M | ||
| Q2 25 | $6.4M | $225.4M | ||
| Q1 25 | $8.1M | $221.0M | ||
| Q4 24 | $7.8M | $231.3M | ||
| Q3 24 | $6.0M | $217.0M | ||
| Q2 24 | $5.5M | $236.8M | ||
| Q1 24 | $7.3M | $228.8M |
净利润ICCCNEOG
| Q4 25 | — | $-15.9M | ||
| Q3 25 | $-139.7K | $36.3M | ||
| Q2 25 | $501.9K | $-612.3M | ||
| Q1 25 | $1.4M | $-10.9M | ||
| Q4 24 | — | $-456.3M | ||
| Q3 24 | $-701.7K | $-12.6M | ||
| Q2 24 | $-1.5M | $-5.4M | ||
| Q1 24 | $-437.9K | $-2.0M |
毛利率ICCCNEOG
| Q4 25 | — | 47.5% | ||
| Q3 25 | 42.9% | 45.4% | ||
| Q2 25 | 43.7% | 41.2% | ||
| Q1 25 | 41.6% | 49.9% | ||
| Q4 24 | 36.5% | 49.0% | ||
| Q3 24 | 26.3% | 48.4% | ||
| Q2 24 | 22.5% | 47.9% | ||
| Q1 24 | 31.6% | 51.1% |
营业利润率ICCCNEOG
| Q4 25 | — | -2.4% | ||
| Q3 25 | 0.4% | -7.7% | ||
| Q2 25 | 8.8% | -271.1% | ||
| Q1 25 | 13.9% | 2.4% | ||
| Q4 24 | 8.0% | -197.8% | ||
| Q3 24 | -9.6% | 1.0% | ||
| Q2 24 | -25.3% | 5.5% | ||
| Q1 24 | -4.1% | 5.3% |
净利率ICCCNEOG
| Q4 25 | — | -7.1% | ||
| Q3 25 | -2.5% | 17.4% | ||
| Q2 25 | 7.8% | -271.6% | ||
| Q1 25 | 17.9% | -4.9% | ||
| Q4 24 | — | -197.3% | ||
| Q3 24 | -11.7% | -5.8% | ||
| Q2 24 | -28.0% | -2.3% | ||
| Q1 24 | -6.0% | -0.9% |
每股收益（稀释后）ICCCNEOG
| Q4 25 | — | $-0.07 | ||
| Q3 25 | $-0.02 | $0.17 | ||
| Q2 25 | $0.06 | $-2.82 | ||
| Q1 25 | $0.16 | $-0.05 | ||
| Q4 24 | $0.09 | $-2.10 | ||
| Q3 24 | $-0.09 | $-0.06 | ||
| Q2 24 | $-0.20 | $-0.02 | ||
| Q1 24 | $-0.06 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.9M | $145.3M |
| 总债务越低越好 | $9.5M | — |
| 股东权益账面价值 | $29.8M | $2.1B |
| 总资产 | $45.7M | $3.4B |
| 负债/权益比越低杠杆越低 | 0.32× | — |
8季度趋势，按日历期对齐
现金及短期投资ICCCNEOG
| Q4 25 | — | $145.3M | ||
| Q3 25 | $3.9M | $138.9M | ||
| Q2 25 | — | $129.0M | ||
| Q1 25 | — | $127.7M | ||
| Q4 24 | $3.8M | $140.2M | ||
| Q3 24 | — | $120.5M | ||
| Q2 24 | $1.3M | $170.9M | ||
| Q1 24 | $960.3K | $168.4M |
总债务ICCCNEOG
| Q4 25 | — | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $9.0M | — | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $9.8M | — | ||
| Q1 24 | $10.2M | — |
股东权益ICCCNEOG
| Q4 25 | — | $2.1B | ||
| Q3 25 | $29.8M | $2.1B | ||
| Q2 25 | $29.9M | $2.1B | ||
| Q1 25 | $29.0M | $2.7B | ||
| Q4 24 | $27.5M | $2.7B | ||
| Q3 24 | $26.4M | $3.1B | ||
| Q2 24 | $23.5M | $3.1B | ||
| Q1 24 | $24.6M | $3.1B |
总资产ICCCNEOG
| Q4 25 | — | $3.4B | ||
| Q3 25 | $45.7M | $3.4B | ||
| Q2 25 | $46.7M | $3.4B | ||
| Q1 25 | $45.6M | $4.0B | ||
| Q4 24 | $45.1M | $4.1B | ||
| Q3 24 | $44.4M | $4.5B | ||
| Q2 24 | $41.9M | $4.5B | ||
| Q1 24 | $43.1M | $4.6B |
负债/权益比ICCCNEOG
| Q4 25 | — | — | ||
| Q3 25 | 0.32× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.42× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $7.8M |
| 自由现金流率自由现金流/营收 | -32.3% | 3.5% |
| 资本支出强度资本支出/营收 | 10.8% | 5.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $715.4K | $-18.5M |
8季度趋势，按日历期对齐
经营现金流ICCCNEOG
| Q4 25 | — | $19.4M | ||
| Q3 25 | $-1.2M | $10.9M | ||
| Q2 25 | $1.6M | $16.4M | ||
| Q1 25 | $1.6M | $19.5M | ||
| Q4 24 | $-3.1K | $40.3M | ||
| Q3 24 | $-639.3K | $-17.9M | ||
| Q2 24 | $581.8K | $26.7M | ||
| Q1 24 | $418.5K | $-30.2M |
自由现金流ICCCNEOG
| Q4 25 | — | $7.8M | ||
| Q3 25 | $-1.8M | $-13.1M | ||
| Q2 25 | $1.4M | $349.0K | ||
| Q1 25 | $1.2M | $-13.4M | ||
| Q4 24 | $-199.3K | $23.1M | ||
| Q3 24 | $-727.7K | $-56.3M | ||
| Q2 24 | $471.0K | $2.5M | ||
| Q1 24 | $348.1K | $-62.3M |
自由现金流率ICCCNEOG
| Q4 25 | — | 3.5% | ||
| Q3 25 | -32.3% | -6.3% | ||
| Q2 25 | 22.4% | 0.2% | ||
| Q1 25 | 15.4% | -6.1% | ||
| Q4 24 | -2.6% | 10.0% | ||
| Q3 24 | -12.1% | -26.0% | ||
| Q2 24 | 8.6% | 1.1% | ||
| Q1 24 | 4.8% | -27.2% |
资本支出强度ICCCNEOG
| Q4 25 | — | 5.2% | ||
| Q3 25 | 10.8% | 11.5% | ||
| Q2 25 | 2.4% | 7.1% | ||
| Q1 25 | 4.1% | 14.9% | ||
| Q4 24 | 2.5% | 7.4% | ||
| Q3 24 | 1.5% | 17.7% | ||
| Q2 24 | 2.0% | 10.2% | ||
| Q1 24 | 1.0% | 14.0% |
现金转化率ICCCNEOG
| Q4 25 | — | — | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | 3.19× | — | ||
| Q1 25 | 1.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICCC
暂无分部数据
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
